Depression Care360

The FDA has approved a new treatment option that is the first drug approved by the FDA specifically for the treatment of postpartum depression in adult women.

The FDA has approved a new nasal spray, in conjunction with an oral antidepressant, for the treatment of adults with treatment-resistant depression.

The FDA Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted on the benefit-risk profile of esketamine nasal spray for the treatment of adults...